Skip Navigation


Rheumatology Advance Access originally published online on March 9, 2005
Rheumatology 2005 44(6):729-734; doi:10.1093/rheumatology/keh583
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
44/6/729    most recent
keh583v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Wijngaarden, S.
Right arrow Articles by Lafeber, F. P. J. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wijngaarden, S.
Right arrow Articles by Lafeber, F. P. J. G.
Related Collections
Right arrow Rheumatoid Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oupjournals.org

Down-regulation of activating Fc{gamma} receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment

S. Wijngaarden1, J. A. G. van Roon1,2, J. G. J. van de Winkel2,3, J. W. J. Bijlsma1 and F. P. J. G. Lafeber1

1 Rheumatology and Clinical Immunology, 2 Immunotherapy Laboratory, Department of Immunology, University Medical Centre Utrecht and 3 Genmab, P.O. Box 85500, 3508 GA Utrecht, The Netherlands.

Correspondence to: J. A. G. van Roon, Department of Rheumatology and Clinical Immunology, University Medical Centre Utrecht, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. E-mail: J.vanRoon{at}azu.nl

Objective. To determine the effect of methotrexate (MTX) on expression levels of activating receptors for IgG (Fc{gamma}Rs) on monocytes of rheumatoid arthritis (RA) patients in relation to changes in disease activity.

Methods. The effect of MTX on Fc{gamma}Rs on monocytes of RA patients was evaluated ex vivo as well as in vitro. Recently diagnosed, disease-modifying antirheumatic drug (DMARD)-naive RA patients were treated with low-dose MTX. At baseline and 16 weeks after the start of MTX treatment, changes in Fc{gamma}R expression levels on peripheral blood monocytes were evaluated by fluorescence-activated cell sorting analysis and were correlated to changes in disease parameters. To study the direct effects of MTX on monocytes, these cells were isolated from peripheral blood monocytes of healthy controls and cultured with MTX. Other monocyte surface molecules (CD40, CD80, CD86, MHC class II) were also determined to test the specificity of the effect on Fc{gamma}R expression levels.

Results. Eleven out of 15 patients improved clinically (mean disease activity score before 6.2 ± 0.8 vs 4.3 ± 1.7 after). Sixteen weeks after the start of MTX therapy, the expression levels of Fc{gamma}RI and IIa on monocytes were significantly decreased, whereas the decreases in Fc{gamma}RIIIa expression levels on monocytes were less marked. The percentage decrease in Fc{gamma}RI expression correlated with the percentage decrease in CRP and well-being. In vitro MTX selectively decreased Fc{gamma}RI and Fc{gamma}RIIa expression levels of isolated monocytes, in contrast to other surface molecules.

Conclusion. The disease-modifying effect of MTX in the treatment of RA is accompanied by down-regulation of activating Fc{gamma}RI and IIa on monocytes, which could be a direct effect of MTX on monocytes. This down-regulation represents a new mode of action of MTX which should be considered in RA patients, especially during conditions that could give rise to monocyte activation by IgG-containing immune complexes, e.g. during antibody-based therapy of RA.

KEY WORDS: Fc{gamma}, receptor, Methotrexate, Rheumatoid arthritis, Monocytes/macrophages


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
J. A. M. Wessels, T. W. J. Huizinga, and H.-J. Guchelaar
Recent insights in the pharmacological actions of methotrexate in the treatment of rheumatoid arthritis
Rheumatology, March 1, 2008; 47(3): 249 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Kastbom, A. Ahmadi, P. Soderkvist, and T. Skogh
The 158V polymorphism of Fc gamma receptor type IIIA in early rheumatoid arthritis: increased susceptibility and severity in male patients (the Swedish TIRA project)
Rheumatology, October 1, 2005; 44(10): 1294 - 1298.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.